Risk-Stratified Treat-to-Target Therapy for IgA Nephropathy

Authored by Sourabh Sharma, published on 2026-11-16 14:14:41.0

  1. Confirm Biopsy-Proven Primary IgAN and Exclude Secondary Causes
    • Is a Special IgAN Presentation Present?
      • Treat With Cyclophosphamide and Systemic Glucocorticoids
      • Coordinate Pregnancy-Specific IgAN and Nephrotic Syndrome Pathways
      • Stop Contraindicated Drugs; Follow Pregnancy-Specific IgAN Pathway
      • Evaluate Minimal Change Pattern; Follow Nephrotic Syndrome Pathway
      • Prioritize CKD Care, Trial Eligibility, and Kidney Replacement Planning
      • Assess eGFR, Proteinuria, BP, Albumin, Hematuria, MEST-C, and Prediction Tool
        • Optimize ACEi/ARB, BP ≤120/70, Lifestyle, and Cardiovascular Risk
          • Proteinuria ≥0.5 g/day or eGFR Decline Despite Care?
            • Continue Effective Therapy and Serial Kidney Surveillance
            • Select the Antiproteinuric Treatment Foundation
              • Replace ACEi/ARB With Sparsentan; Add SGLT2i When Eligible
                • Select Preferred IgA-Directed Disease-Modifying Therapy
                  • Start Targeted-Release Budesonide (Nefecon)
                    • Reassess Proteinuria, eGFR Trend, BP, Adherence, and Treatment Safety
                      • Proteinuria <0.5 g/day, Ideally <0.3, With Stable eGFR?
                        • Continue Effective Therapy and Serial Kidney Surveillance
                        • Reassess Diagnosis and Layer Alternative Therapy or Clinical Trial
                  • Start MMF in Appropriate Chinese Patients
                    • Reassess Proteinuria, eGFR Trend, BP, Adherence, and Treatment Safety
                      • Proteinuria <0.5 g/day, Ideally <0.3, With Stable eGFR?
                        • Continue Effective Therapy and Serial Kidney Surveillance
                        • Reassess Diagnosis and Layer Alternative Therapy or Clinical Trial
                  • Start Reduced-Dose Systemic Glucocorticoids With Infection Prophylaxis
                    • Reassess Proteinuria, eGFR Trend, BP, Adherence, and Treatment Safety
                      • Proteinuria <0.5 g/day, Ideally <0.3, With Stable eGFR?
                        • Continue Effective Therapy and Serial Kidney Surveillance
                        • Reassess Diagnosis and Layer Alternative Therapy or Clinical Trial
                  • Continue Nephron Protection and Pursue a Clinical Trial
                    • Reassess Proteinuria, eGFR Trend, BP, Adherence, and Treatment Safety
                      • Proteinuria <0.5 g/day, Ideally <0.3, With Stable eGFR?
                        • Continue Effective Therapy and Serial Kidney Surveillance
                        • Reassess Diagnosis and Layer Alternative Therapy or Clinical Trial
              • Continue Max-Tolerated ACEi/ARB; Add SGLT2i When Eligible
                • Select Preferred IgA-Directed Disease-Modifying Therapy
                  • Start Targeted-Release Budesonide (Nefecon)
                    • Reassess Proteinuria, eGFR Trend, BP, Adherence, and Treatment Safety
                      • Proteinuria <0.5 g/day, Ideally <0.3, With Stable eGFR?
                        • Continue Effective Therapy and Serial Kidney Surveillance
                        • Reassess Diagnosis and Layer Alternative Therapy or Clinical Trial
                  • Start MMF in Appropriate Chinese Patients
                    • Reassess Proteinuria, eGFR Trend, BP, Adherence, and Treatment Safety
                      • Proteinuria <0.5 g/day, Ideally <0.3, With Stable eGFR?
                        • Continue Effective Therapy and Serial Kidney Surveillance
                        • Reassess Diagnosis and Layer Alternative Therapy or Clinical Trial
                  • Start Reduced-Dose Systemic Glucocorticoids With Infection Prophylaxis
                    • Reassess Proteinuria, eGFR Trend, BP, Adherence, and Treatment Safety
                      • Proteinuria <0.5 g/day, Ideally <0.3, With Stable eGFR?
                        • Continue Effective Therapy and Serial Kidney Surveillance
                        • Reassess Diagnosis and Layer Alternative Therapy or Clinical Trial
                  • Continue Nephron Protection and Pursue a Clinical Trial
                    • Reassess Proteinuria, eGFR Trend, BP, Adherence, and Treatment Safety
                      • Proteinuria <0.5 g/day, Ideally <0.3, With Stable eGFR?
                        • Continue Effective Therapy and Serial Kidney Surveillance
                        • Reassess Diagnosis and Layer Alternative Therapy or Clinical Trial
  2. Use MEST-C and Prediction Tool for Prognosis, Not Standalone Treatment Selection
  3. Screen Pregnancy, Infection, Hepatic, Metabolic, and Glucocorticoid Risks
tosprivacy